Peptides DB
Research-centric peptide and protocol reference hub
Study 33 of 33Tirzepatide literatureAmerican heart journal plus : cardiology research and practice · Observational2026

Cardiovascular outcomes with semaglutide versus tirzepatide in patients with obesity and atherosclerotic cardiovascular disease without diabetes.

Semaglutide and tirzepatide appear to have similar cardiovascular outcomes in patients with obesity and ASCVD, according to this study.

Read at American heart journal plus : cardiology research and practiceAdd to compare

Where it sits

this study against the rest of the tirzepatide corpus
4
Preclinical
21
Observational · this one
1
Open-label
4
Randomised
3
Reviews

Summary and findings

This study compared cardiovascular outcomes between semaglutide and tirzepatide in adults with obesity and atherosclerotic cardiovascular disease. A total of 5665 patients were analyzed per group, with no statistically significant differences in major adverse cardiovascular events. The findings suggest similar cardiovascular outcomes for both treatments.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
19.5% 5-point MACE for semaglutide vs 17.1% for tirzepatide, HR 1.03, 95% CI 0.94-1.12.n=113302026

Abstract

The authors’ words, as American heart journal plus : cardiology research and practice supplied them

<h4>Background</h4>Comparative cardiovascular data on glucagon-like peptide-1 (GLP-1) agonists versus dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists in atherosclerotic cardiovascular disease (ASCVD) without diabetes are limited.<h4>Methods</h4>This propensity score-matched retrospective TriNetX study compared adults aged ≥45 years with body mass index ≥27 kg/m<sup>2</sup> and ASCVD initiating treatment with semaglutide or tirzepatide. Hazard ratios (HRs) with 95% confidence intervals (CIs) were used to analyze 3-point major adverse cardiovascular events (MACE: all-cause mortality, myocardial infarction, or ischemic stroke) and 5-point MACE (3-point MACE plus heart failure exacerbation and revascularization).<h4>Results</h4>After matching, 5665 patients were analyzed per group. No statistically significant differences were observed between semaglutide and tirzepatide in 5-point MACE (19.5% vs 17.1%; HR 1.03; 95% CI 0.94-1.12), 3-point MACE (17.4% vs 15.4%; HR 1.04; 95% CI 0.95-1.14), or any individual component.<h4>Conclusions</h4>Semaglutide and tirzepatide were associated with similar cardiovascular outcomes. Prospective head-to-head trials are warranted to validate these results.

Background

This paper addresses the comparative cardiovascular outcomes of glucagon-like peptide-1 (GLP-1) agonists versus dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonists in patients with atherosclerotic cardiovascular disease (ASCVD) without diabetes. Previous studies have shown varying cardiovascular effects of GLP-1 agonists, but data comparing these specific agents in this population are limited. Understanding these outcomes is crucial for guiding treatment decisions in patients with obesity and ASCVD.

Methods

The study employed a propensity score-matched retrospective design, focusing on adults aged ≥45 years with a body mass index ≥27 kg/m² and ASCVD. A total of 5665 patients initiating treatment with either semaglutide or tirzepatide were analyzed. The primary outcome measures included 3-point major adverse cardiovascular events (MACE) and 5-point MACE, which included additional components such as heart failure exacerbation and revascularization.

Results

The primary endpoint for 5-point MACE showed no statistically significant difference between semaglutide and tirzepatide, with rates of 19.5% and 17.1%, respectively (HR 1.03; 95% CI 0.94-1.12). Similarly, for 3-point MACE, the rates were 17.4% for semaglutide and 15.4% for tirzepatide (HR 1.04; 95% CI 0.95-1.14). No significant differences were observed for any individual component of the outcomes measured.

Interpretation

The findings suggest that semaglutide and tirzepatide are associated with similar cardiovascular outcomes in this specific patient population. While the hazard ratios indicate no significant differences, the effect sizes are small, which raises questions about clinical relevance. The retrospective nature of the study and reliance on propensity score matching introduce potential confounding factors that limit the conclusions that can be drawn. Further prospective head-to-head trials are warranted to validate these results and clarify the implications for clinical practice.

Key findings

  • 5-point MACE: 19.5% semaglutide vs 17.1% tirzepatide; HR 1.03; 95% CI 0.94-1.12.
  • 3-point MACE: 17.4% semaglutide vs 15.4% tirzepatide; HR 1.04; 95% CI 0.95-1.14.
  • 5665 patients analyzed per group.

Limitations

  • retrospective design may introduce bias
  • propensity score matching may not account for all confounders
  • small effect sizes raise questions about clinical relevance
  • no individual component showed significant differences
  • further prospective trials needed to validate results

Elsewhere in the Tirzepatide corpus

AIxekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2026 · 31.7% IXE + TZP vs 0.8% IXE alone at 36 weeks, P<0.001.HumanBTirzepatide Versus Conventional Glucagon-Like Peptide-1 Receptor Agonists for Treatment Simplification in Type 2 Diabetes Mellitus: A Real-World Study.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026 · Odds ratio: 3.69, 95% confidence interval: 2.21-6.16; P < .001.HumanCEnsemble-Based Segmental Helical Organization in an Aib-Rich Lipidated Peptide: Biomacromolecular Insights from High-Field NMR.Biomacromolecules · 2026 · Not reported in abstract.In vitroB12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study.Obesity pillars · 2026 · n=249 · Mean weight loss was 19.9 ± 8.6% at 12 months.HumanBReal-world, digital-first delivery of GLP-1 receptor agonist therapy in women.Nature medicine · 2026 · Mean weight reduction was 16.1 kg (95% CI 15.9 to 16.2; P < 0.001).HumanAEvaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.Obesity pillars · 2026 · Mean weight regain from nadir to Week 176 was 3.8 kg for 5 mg, 4.4 kg for 10 mg, and 3.7 kg for 15 mg.Human